Actinium Pharmaceuticals, a leader in targeted radiotherapies, has announced that two of its research abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, scheduled for April 17–22 in San Diego, California.

The presentations, set for April 21 in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology, will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies.

“These new data further validate the strength and versatility of our Ac-225 radiotherapy platform,” said Sandesh Seth, Actinium’s Chairman and CEO.

“ATNM-400 continues to show compelling pan-tumor activity, including activity in tumors resistant to current targeted therapies, supporting its potential as a first-in-class asset in large solid tumor indications.

"In parallel, Actimab-A's newly identified mechanism of transcriptional reprogramming provides important insight into its mutation-agnostic activity and ability to enhance standard-of-care therapies. Together, these findings reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities.”